[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.190.122. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1980

5-Hydroxytryptophan and Pyridoxine: Their Effects in Young Children With Down's Syndrome

Author Affiliations

From the Child Development Center, Rhode Island Hospital, Department of Pediatrics, Section on Reproductive and Developmental Medicine, Brown University, Providence, RI (Dr Pueschel); and the Developmental Evaluation Clinic, Department of Medicine, Children's Hospital Medical Center, Department of Pediatrics, Harvard Medical School (Ms Cronk), the Department of Biostatistics, Harvard School of Public Health (Dr Reed), and the Harvard School of Dental Medicine (Ms Goldstein), Boston.

Am J Dis Child. 1980;134(9):838-844. doi:10.1001/archpedi.1980.02130210022007
Abstract

• In a double-blind study, 89 children with Down's syndrome were given 5-hydroxytryptophan or pyridoxine hydrochloride in the first three years of life. The analysis of 5-hydroxyindole blood levels revealed that 5-hydroxytryptophan, pyridoxine, and the combination of 5-hydroxytryptophan and pyridoxine raised blood levels of 5-hydroxyindole equally well in 40% of the children. The assessment of muscle-tone ratings showed no significant difference among the study groups once children with moderate and severe congenital heart disease were excluded. Detailed studies of cognitive-adaptive function of children in the various groups found a significant difference on the Vineland Social Maturity Scale at ages 6, 12, 18, and 36 months; yet the source of significance was a negative interaction affecting children whose parents were able to comply with furnished guidance; these children showed consistently higher levels of accomplishment.

(Am J Dis Child 134:838-844, 1980)

×